Stem Cell Authority Ltd
Stem Cell Authority, Ltd., a technology development company, focuses on the collection and cryogenic preservation of stem cells. It specializes in the collection and cryogenic preservation of the hematopoietic stem cells from the umbilical cord blood; and the Miracle Mesenchymal stem cells from the Wharton's jelly inside the umbilical cord of a newborn child. The company's technology enables birt… Read more
Stem Cell Authority Ltd (SCAL) - Total Liabilities
Latest total liabilities as of May 2007: $2.27 Million USD
Based on the latest financial reports, Stem Cell Authority Ltd (SCAL) has total liabilities worth $2.27 Million USD as of May 2007.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Stem Cell Authority Ltd - Total Liabilities Trend (2001–2009)
This chart illustrates how Stem Cell Authority Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Stem Cell Authority Ltd Competitors by Total Liabilities
The table below lists competitors of Stem Cell Authority Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Fidelity Holding Corp
PINK:FDHC
|
USA | $50.00K |
|
MobiVentures Inc
PINK:MBLV
|
USA | $38.98K |
|
KS International Holdings Corporation
PINK:KSIH
|
USA | $151.44K |
|
Coil Tubing Technology Inc
PINK:CTBG
|
USA | $5.75 Million |
|
Sortis Holdings Inc
PINK:SOHI
|
USA | $593.82K |
|
Oct 88 Res Inc
PINK:OCTX
|
USA | $115.54K |
|
RONN Inc.
PINK:RONN
|
USA | $9.99 Million |
Liability Composition Analysis (2001–2009)
This chart breaks down Stem Cell Authority Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.13 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 4.99 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.83 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Stem Cell Authority Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Stem Cell Authority Ltd (2001–2009)
The table below shows the annual total liabilities of Stem Cell Authority Ltd from 2001 to 2009.
| Year | Total Liabilities | Change |
|---|---|---|
| 2009-08-31 | $4.08 Million | +56.61% |
| 2008-08-31 | $2.60 Million | +64.85% |
| 2007-08-31 | $1.58 Million | +8.13% |
| 2006-08-31 | $1.46 Million | +1714.10% |
| 2002-08-31 | $80.53K | +105.34% |
| 2001-08-31 | $39.22K | -- |